This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

William L. Ashton Joins Galena Biopharma's Board Of Directors

LAKE OSWEGO, Ore., May 1, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the addition of William L. Ashton to the Company's Board of Directors.

Mr. Ashton is a senior executive with more than twenty-eight years of experience in biotechnology and pharmaceutical leadership and management. Most recently, at Amgen, Inc., he served as Vice President of corporate and government affairs and Vice President of sales, and was directly responsible for product launches, as well as key government agencies including Centers for Medicare and Medicaid Services, Office of Inspector General, General Accounting Office, Office of Management and Budget, and MedPAC.

"Bill brings an enormous wealth of commercial experience and expertise in pharmaceutical sales, leadership and corporate affairs that will be invaluable to Galena as we move forward into commercialization this year," said Mark J. Ahn, Ph.D., President and Chief Executive Officer of Galena Biopharma. "We look forward to his contributions and guidance in establishing Abstral® as the best in class leader in breakthrough cancer pain, as well as preparing for NeuVax™ commercialization."

After retiring from Amgen, Mr. Ashton joined the University of the Sciences in Philadelphia where he currently serves as Associate Provost and Senior Vice President of Strategic Business Development, Founding Dean, Mayes College of Healthcare Business and Policy, and Assistant Professor of Pharmaceutical Business.

Mr. Ashton is on the boards of the National Osteoporosis Foundation, Friends of the National Library of Medicine (NIH), and a commissioner for the Medical Representatives National Certificate Commission. He currently serves on the board of Sucampo Pharmaceuticals. He received his Bachelor of Science from California University of Pennsylvania and his Master of Science from the University of Pittsburgh.

"Galena has made exceptional progress over the last few years, and I am excited to join the Board of Directors as the company initiates commercialization. With NeuVax enrolling its Phase 3 trial and the commercialization of Abstral expected this year, I look forward to providing my support and guidance as we work to enhance the treatment of cancer patients," added William L. Ashton.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs